传统观点一直认为卵巢低级别浆液性癌与其他上皮性卵巢癌一样起源于卵巢表面上皮。我们在近期工作基础上提出卵巢低级别浆液性癌起源于输卵管的假说：输卵管上皮细胞脱落→附着到卵巢表面→输卵管源包涵体→卵巢浆液性囊腺瘤→卵巢交界性浆液性肿瘤→卵巢低级别浆液性癌。本研究用激光捕获显微切割技术获取输卵管上皮、卵巢表面上皮、包涵体、浆液性囊腺瘤、交界性浆液性肿瘤、低级别浆液性癌组织，利用Gemini蛋白组学系统进行蛋白表达谱分析；分析各种组织的表达谱验证卵巢低级别浆液性癌起源于输卵管的假说；筛选可能导致卵巢低级别浆液性癌发生发展的关键分子如RID1A、53BP1和HRAS，并利用体外、体内实验分析它们在低级别浆液性癌发生发展过程中的作用；免疫组化分析RID1A、53BP1和HRAS与肿瘤发生发展和临床预后的相关性。本研究将为明确卵巢低级别浆液性癌的起源提供分子水平的证据，为肿瘤标志物的筛选和诊断提供依据。

Low grade serous ovarian cancer(LG-SC) is thought to be derived from Ovarian Surface Epithelia（OSE）. Based on pathological and immunohistochemical studies of ovarian normal tissues and serous tumor tissues, we proposed that the "ovarian" LG-SC is likely to be derived from oviduct（fallopian tube）epithiliam.Tubal epithelia are able to stuck on ovarian surface invaginate into the ovarian stroma to form ovarian epithelial inclusions (OEIs).Serous tumors including serous cystadenoma, serous borderline tumor, and LG-SC develop afterwards. In this study, Calibrant's Gemini? platform was used for proteomics analysis on OSE,OEI,benign,bordline and cancerous tissues isolated by Laser capture microdissection (LCM).The first aim of this study is to confirm the oviduct origin of LG-SC by proteomics analysis. Then we chose RID1A, 53BP1and HRAS(Dysregulated in LG-SC) to study their roles in tumorigenesis and progression. At last we will use immunohistochemical analysis to test the correlation between these protein expression and tumor progression or overall survival.This study will clarify the origin and progression of LG-SC and identify tumor markers for early diagnosis and molecular treatment.